1. Name and Address of Reporting Person
BOCK LOUIS C
C/O SCALE VENTURE MANAGEMENT II, LLC
950 TOWER LN., SUITE 700
FOSTER CITY CA 94404

2. Date of Event Requiring Statement
07/28/2011

3. Issuer Name and Ticker or Trading Symbol
HORIZON PHARMA, INC. [HZNP]

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
X Director (Instr. 5)
10% Owner (Instr. 5)
Other (specify below)

5. If Amendment, Date of Original Filed

6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 4)</th>
<th>2. Amount of Securities Beneficially Owned (Instr. 4)</th>
<th>3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</th>
<th>4. Nature of Indirect Beneficial Ownership (Instr. 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>1,370,070</td>
<td>1</td>
<td>See Footnote(2)</td>
</tr>
<tr>
<td>Common Stock</td>
<td>171,626</td>
<td>I</td>
<td>See Footnote(2)</td>
</tr>
<tr>
<td>Common Stock</td>
<td>3,117,469.92</td>
<td>I</td>
<td>See Footnote(2)</td>
</tr>
<tr>
<td>Series A Preferred Stock</td>
<td>69,451</td>
<td>5.201</td>
<td>See Footnote(2)</td>
</tr>
<tr>
<td>Series A Preferred Stock</td>
<td>34,726</td>
<td>5.201</td>
<td>See Footnote(2)</td>
</tr>
<tr>
<td>Series A Preferred Stock</td>
<td>43,409</td>
<td>5.201</td>
<td>See Footnote(2)</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 4)</th>
<th>2. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)</th>
<th>4. Conversion or Exercise Price of Derivative Security</th>
<th>5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</th>
<th>6. Nature of Indirect Beneficial Ownership (Instr. 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Series A Preferred Stock</td>
<td>10/31/2015(4)</td>
<td>Series A Preferred Stock</td>
<td>69,451</td>
<td>1</td>
<td>See Footnote(2)</td>
</tr>
<tr>
<td>Warrant to Purchase Series A Preferred Stock</td>
<td>07/02/2016(4)</td>
<td>Series A Preferred Stock</td>
<td>34,726</td>
<td>1</td>
<td>See Footnote(2)</td>
</tr>
<tr>
<td>Warrant to Purchase Series A Preferred Stock</td>
<td>09/25/2016(4)</td>
<td>Series A Preferred Stock</td>
<td>43,409</td>
<td>1</td>
<td>See Footnote(2)</td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. The shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date and are convertible at any time at the election of the holder. Every 2,374 shares of preferred stock will automatically convert into one share of common stock upon the closing of the Issuer's initial public offering.
2. Held of record by Scale Venture Partners II, LP ("Scale Partners"). The General Partner of Scale Partners is Scale Venture Management II, LLC ("Scale Management"). The Reporting Person is a member of Scale Management. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.
3. Principal and accrued interest will convert upon the Issuer's initial public offering into shares of Common Stock at a conversion price equal to the lesser of (i) the public offering price of the Common Stock sold in the Issuer's initial public offering, or (ii) $18.92. Amounts shown are reported in US dollars and include interest accrued through the date hereof; additional interest will accrue prior to conversion.
4. The warrants are immediately exercisable and shall terminate on the earlier of the expiration date referenced above or the occurrence of other specified corporate transactions.

/s/ Louis C. Bock
07/28/2011
** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.